Curve Therapeutics, a University of Southampton spinout focused on transcription factors and other intracellular targets, appointed liver specialist Amit Singal to join its leadership as CMO. Singal, who is chief of hepatology at UT Southwestern Medical Center, led work connected to recent American Association for the Study of Liver Diseases (AASLD) practice guidance for cirrhosis monitoring and management. The move signals Curve’s intent to strengthen clinical development capabilities as it advances programs that may require broader therapeutic-area execution beyond oncology. For investors and partners, the appointment adds a seasoned clinician to guide trial strategy and execution.